• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Rapport Therapeutics (RAPP) Fairly Valued After Its Positive Phase 2 Bipolar Mania Data?

    Simply Wall St·10/22/2026 14:36:37
    Listen to the news

    Rapport Therapeutics (RAPP) has put fresh clinical data at the center of the story. Positive topline Phase 2 results for RAP-219 in acute bipolar I mania now frame how investors weigh the stock.

    Despite the positive trial update, Rapport Therapeutics has seen momentum cool. The share price is at $25.06 after a 1-day share price return of down 14.67%, a 30-day share price return of down 36.81%, and a 1-year total shareholder return of 0.64%, which now looks far more muted than the earlier reaction implied.

    Scan how Rapport Therapeutics fits alongside other clinically focused biopharma stocks by checking the hand-picked 37 healthcare AI stocks that are also tied to major trial milestones.

    Bulls see proof of concept in bipolar mania worth far more than a $1.41b firm that is already off its highs. Bears point to modest effect size and a long road to Phase 3. Which side does the current valuation echo?

    Preferred Price-to-Book Multiple of 2.8x: Is It Justified?

    Valuation for Rapport Therapeutics currently hinges on its P/B ratio of 2.8x at a share price of $25.06, which screens as more expensive than the broader US Pharmaceuticals industry but lower than closer peers.

    The P/B ratio compares a company’s market value to its book value, which is effectively the accounting value of its net assets. For a clinical-stage biopharma like Rapport Therapeutics that is still loss making, investors often lean on this metric because earnings based ratios are less meaningful while products are in development.

    In this case, the stock trades at a P/B of 2.8x, above the wider US Pharmaceuticals average of 1.9x. That points to investors paying a richer price per dollar of net assets than they do for the typical pharma business. Against a more focused peer set, where the average P/B is 9.5x, Rapport Therapeutics comes through as comparatively cheaper. This highlights a valuation gap that the market could potentially close in either direction over time.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 2.8x (ABOUT RIGHT)

    Still, the Rapport Therapeutics story faces clear pressure if future RAP-219 readouts underwhelm or if ongoing losses of $137.16m strain investor patience.

    Find out about the key risks to this Rapport Therapeutics narrative.

    Next Steps

    Conflicted by the mix of pressure and promise around Rapport Therapeutics right now? Review the full spread of data, act promptly while sentiment continues to shift, and carefully weigh the 1 key reward and 2 important warning signs

    Looking For More Ideas Beyond Rapport Therapeutics?

    Do not stop your research with Rapport Therapeutics alone. Broaden your watchlist with other opportunities that fit clear themes, so you are not caught reacting late.